# Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL

> **NCT00072007** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 43 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** rituximab
- **DRUG:** CHOP regimen
- **DRUG:** cladribine
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00072007
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2003-03
- **Final completion:** 2010-10
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2012-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072007, "Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00072007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*